Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing
Published . Updated .
Key takeaways
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest and never sell or share it. See our privacy policy.
Concerns that well-funded Chinese companies will swoop in to grab new ideas for their own drug development are shaping an industry unaccustomed to such secrecy.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- XBI SPDR S&P Biotech ETF
SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story.
- FXI iShares China Large-Cap ETF-2.0% 30d
iShares China Large-Cap ETF holds stocks listed in China, which this story is about (“chinese”).
- LLY Eli Lilly and+25.1% 30d
Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- JNJ Johnson & Johnson+12.1% 30d
Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- PFE Pfizer+5.2% 30d
Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
- MRK Merck+3.5% 30d
Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| XLV | +0.52% | -0.04% | base | after close | after close | after close | after close |
| XBI | +6.26% | +3.61% | base | after close | after close | after close | after close |
| FXI | +3.30% | +0.50% | base | after close | after close | after close | after close |
| LLY | -0.12% | -0.28% | base | after close | after close | after close | after close |
| JNJ | -0.65% | +0.33% | base | after close | after close | after close | after close |
| PFE | +1.66% | -0.17% | base | after close | after close | after close | after close |
| MRK | +2.39% | +1.67% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Concerns that well-funded Chinese companies will swoop in to grab new ideas for their own drug development are shaping an industry unaccustomed to such secrecy.
Source: The New York Times
The price since 17 Nov 2026: Select Sector Spdr Tr (XLV) versus the S&P 500
| Company | When | Move | Status |
|---|---|---|---|
| Ishares China Large-Cap Etf (FXI) | three days earlier | +0.50% | final price |
| Ishares China Large-Cap Etf (FXI) | five days earlier | +3.30% | final price |
| Johnson & Johnson (JNJ) | three days earlier | +0.33% | final price |
| Johnson & Johnson (JNJ) | five days earlier | -0.65% | final price |
| Eli Lilly (LLY) | three days earlier | -0.28% | final price |
| Eli Lilly (LLY) | five days earlier | -0.12% | final price |
| Merck (MRK) | three days earlier | +1.67% | final price |
| Merck (MRK) | five days earlier | +2.39% | final price |
| Pfizer (PFE) | three days earlier | -0.17% | final price |
| Pfizer (PFE) | five days earlier | +1.66% | final price |
| Spdr Series Trust (XBI) | three days earlier | +3.61% | final price |
| Spdr Series Trust (XBI) | five days earlier | +6.26% | final price |
| Select Sector Spdr Tr (XLV) | three days earlier | -0.04% | final price |
| Select Sector Spdr Tr (XLV) | five days earlier | +0.52% | final price |
Trades by members of Congress and officials in the stocks in this story
- Rep. David J. Taylor sold Eli Lilly (LLY), worth $1,001 - $15,000 on 3 Nov 2026. That is 14 days before publication. Filed 12 Nov 2026. View the filing.
- Rep. Gilbert Cisneros bought Eli Lilly (LLY), worth $1,001 - $15,000 on 20 Oct 2026. That is 28 days before publication. Filed 10 Nov 2026. View the filing.
- Rep. Rohit Khanna bought Eli Lilly (LLY) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Johnson & Johnson (JNJ) (held by a spouse), worth $15,001 - $50,000 on 7 Oct 2026. That is 41 days before publication. Filed 5 Nov 2026. View the filing.
- Rep. Thomas H. Kean Jr sold Johnson & Johnson (JNJ), worth $1,001 - $15,000 on 30 Sep 2026. That is 48 days before publication. Filed 30 Oct 2026. View the filing.
- Rep. Rohit Khanna bought Johnson & Johnson (JNJ) (held by a spouse), worth $1,001 - $15,000 on 25 Sep 2026. That is 53 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Rohit Khanna sold Pfizer (PFE) (held by a spouse), worth $1,001 - $15,000 on 4 Sep 2026. That is 74 days before publication. Filed 7 Oct 2026. View the filing.
- Donald J Trump, an executive branch official, bought Pfizer (PFE), worth $100,001 - $250,000 on 21 Aug 2026. That is 88 days before publication. Filed 8 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar sold Merck (MRK), worth $1,001 - $15,000 on 24 Sep 2026. That is 54 days before publication. Filed 7 Oct 2026. View the filing.
- Rep. Maria Elvira Salazar bought Merck (MRK), worth $15,001 - $50,000 on 19 Aug 2026. That is 90 days before publication. Filed 9 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Select Sector Spdr Tr (XLV)
Companies mentioned with this story
- XLV Select Sector Spdr Tr
Select Sector Spdr Tr (XLV) is linked, with no stored direction, medium confidence in the 17 Nov 2026 story “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing.” Reason on file: Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- XBI Spdr Series Trust
In “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing,” Spdr Series Trust (XBI) is linked, with no stored direction, medium confidence. Reason on file: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
- FXI Ishares China Large-Cap Etf
Ishares China Large-Cap Etf (FXI) is linked, with no stored direction, medium confidence in the 17 Nov 2026 story “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing.” Reason on file: iShares China Large-Cap ETF holds stocks listed in China, which this story is about (“chinese”)
- LLY Eli Lilly
In “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing,” Eli Lilly (LLY) is linked, with no stored direction, medium confidence. Reason on file: Eli Lilly and (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- JNJ Johnson & Johnson
In “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing,” Johnson & Johnson (JNJ) is linked, with no stored direction, medium confidence. Reason on file: Johnson & Johnson (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- PFE Pfizer
Pfizer (PFE) is linked, with no stored direction, medium confidence in the 17 Nov 2026 story “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing.” Reason on file: Pfizer (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
- MRK Merck
In “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing,” Merck (MRK) is linked, with no stored direction, medium confidence. Reason on file: Merck (pharmaceutical preparations): drugmakers move with drug pricing, approvals and health policy. Linked by “biotech” (pharma and health) in this story
Select Sector Spdr Tr (XLV)
On 17 Nov 2026, “Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing” is the story that connects Select Sector Spdr Tr (XLV) to this story.
For Select Sector Spdr Tr (XLV), the reason on file says Health Care Select Sector SPDR: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
A second company, Spdr Series Trust (XBI), is listed for a different reason: SPDR S&P Biotech ETF: it holds drugmakers and health companies. Linked by “biotech” (pharma and health) in this story
The price range for Select Sector Spdr Tr (XLV), and the dates in the story
FXI traded between 32.14 and 34.36 across 20 sessions. The latest close on file is 33.21.
How strong the case is around Select Sector Spdr Tr (XLV)
46 out of 100
“Fearing Chinese Rivals, U.S. Biotech Adopts a New Norm: Share Nothing” scores 46 out of 100. The score uses 1 source, and 7 linked companies.